Sonia Pulgar
Overview
Explore the profile of Sonia Pulgar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
137
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vidal G, Gautam S, Vlahiotis A, Fisher M, Pulgar S, DeBusk K
Future Oncol
. 2021 Nov;
18(7):849-858.
PMID: 34756117
To describe real-world treatment patterns/outcomes among patients with HER2+ metastatic breast cancer (MBC). Real-world treatments and overall survival (OS) were evaluated among adult women diagnosed with HER2+ MBC, with and...
2.
Alholm Z, Monk B, Ting J, Pulgar S, Boyd M, Sudharshan L, et al.
Gynecol Oncol
. 2021 Mar;
161(2):422-428.
PMID: 33741208
Objective: There is no standard systemic treatment for recurrent or metastatic cervical cancer (r/mCC) after failure of first-line (1L) therapy. This study characterizes the patient experience, treatment patterns, and clinical...
3.
Barzi A, Miksad R, Surinach A, Corvino F, Wang S, Torres A, et al.
Pancreas
. 2020 Feb;
49(2):193-200.
PMID: 32011529
Objectives: Liposomal irinotecan (nal-IRI) is a topoisomerase inhibitor proven to improve survival in metastatic pancreatic cancer (mPC). This study describes real-world characteristics of patients treated with nal-IRI for mPC. Methods:...
4.
Adams J, Ray D, Willmon R, Pulgar S, Dasari A
JCO Clin Cancer Inform
. 2019 Jul;
3:1-10.
PMID: 31283354
Purpose: To understand the quality of life (QoL) for patients with neuroendocrine tumors (NETs) through comparison of QoL questionnaires and symptom tracking as well as journaling via the Carcinoid NETs...
5.
Pulgar S, Bains S, Gooch J, Chambers H, Noritz G, Wright E, et al.
J Manag Care Spec Pharm
. 2019 Jun;
25(7):817-822.
PMID: 31232210
Background: In the United States, many children with cerebral palsy (CP) obtain health care coverage through managed Medicaid, but little is known about the current demographics or management of this...
6.
Klink A, Feinberg B, Yu H, Ray D, Pulgar S, Phan A, et al.
Oncologist
. 2019 Apr;
24(10):1331-1339.
PMID: 31015313
Background: Although recent pivotal trials (PROMID, CLARINET) have established somatostatin analogs (SSAs) as first-line agents for neuroendocrine tumors (NETs), their use in clinical practice is largely unknown. We aimed to...
7.
Fisher M, Pulgar S, Kulke M, Mirakhur B, Miller P, Walker M, et al.
J Gastrointest Cancer
. 2018 Aug;
50(4):816-823.
PMID: 30121904
Purpose: Metastatic neuroendocrine tumors (mNETs) are rare, heterogeneous tumors that present diagnostic and treatment challenges, with limited data on the management of mNETs in clinical practice. The present study was...
8.
Jiao X, Pulgar S, Boyd M, Braiteh F, Mirakhur B, Lowenthal S, et al.
Pancreas
. 2017 Dec;
47(2):173-182.
PMID: 29206668
Objective: This study was conducted to understand treatment patterns and clinical outcomes in metastatic gastroenteropancreatic neuroendocrine tumor patients treated in a large community oncology network. Methods: This retrospective study used...
9.
Sanderson J, Camba G, Hansen R, Bains S, Pulgar S, Snyder D, et al.
PM R
. 2016 Sep;
8(9S):S321.
PMID: 27673237
No abstract available.
10.
Clarke N, Camba G, Stephens J, Pulgar S, Bains S, Marchese D, et al.
PM R
. 2016 Sep;
8(9S):S316.
PMID: 27673223
No abstract available.